

VIDENSKAB OG PRAKSIS | OVERSIGTSARTIKEL

6. Ponder BAJ. Inherited predisposition to cancer *Trends Genet* 1990;6:213-8.
7. Cannon-Albright LA, Thomas A, Goldgar DE et al. Familiality of cancer in Utah. *Cancer Res* 1994;54:2378-85.
8. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF et al. Cancer as a complex phenotype, pattern of cancer distribution within and beyond the nuclear family. *PLOS Med* 2004;1:229-36.
9. Ögmundsdottir HM, Haraldsdottir V, Johannesson G et al. Familiality of benign and malignant paraproteinemias, a population-based cancer registry study of multiple myeloma families. *Haematologica* 2005;90:66-71.
10. Goldin LR, Pfeiffer RM, Li X et al. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia, results from the Swedish family-cancer database. *Blood* 2004;104:1850-4.
11. Goldin LR, Pfeiffer RM, Gridley G et al. Familial aggregation of Hodgkin lymphoma and related tumors. *Cancer* 2004;100:1902-8.
12. Goldin LR, Landgren O, McMaster ML et al. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. *Cancer Epidemiol Biomark Prev* 2005;14:2402-6.
13. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. *N Engl J Med* 2005;352:804-15.
14. Yuille MR, Houlston RS, Catovsky D. Anticipation in familial chronic lymphocytic leukemia families. *Leukemia* 1998;12:1696-8.
15. Daugherty SE, Pfeiffer RM, Mellemkjaer L et al. No evidence for anticipation in lymphoproliferative tumors in population-based samples. *Cancer Epidemiol Biomarkers Prev* 2005;14:1245-50.
16. Peto J, Houlston RS. Genetics and the common cancers *Eur J Cancer* 2001;37:S88-96.
17. Houlston RS, Peto J. The future of association studies of common cancers. *Hum Genet* 2003;112:434-5.
18. Hervé M, Xu K, Ng YS et al. Unmutated and mutated chronic lymphocytic leukemia derived from self-reactive B cell precursors despite expression different antibody reactivity. *J Clin Invest* 2005;115:1636-43.
19. Rawstron AC, Yuille MR, Fuller J et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. *Blood* 2002;100:2289-90.
20. Muller-Hermelink HK, Catovsky D, Montserrat E et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. I: Jaffe E, Harris NL, Stein H et al, red. *Tumours of haematopoietic and lymphoid tissues*. Lyon: IARC Press, 2001:127-30.
21. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000;343:1910-6.
22. Rawstron A, Hillmen P, Houlston R. Clonal lymphocytes in persons without known chronic lymphocytic leukemia, implications of recent findings in family members of CLL patients. *Semin Hematol* 2004;41:192-200.
23. Yuille MR, Matutes E, Marossy A et al. Familial chronic lymphocytic leukaemia, a survey and review of published studies. *Br J Haematol* 2000;109:794-9.
24. Houlston RS, Sellick G, Yuille M et al. Causation of chronic lymphocytic leukemia, insights from familial disease. *Leuk Res* 2003;27:871-6.
25. Sellick GS, Webb EL, Allinson R et al. A high-density SNP genome-wide linkage scan for chronic lymphocytic leukemia-susceptibility loci. *Am J Hum Genet* 2005;77:420-9.
26. Bevan S, Catovsky D, Marossy A et al. Linkage analysis for ATM in familial chronic lymphocytic leukemia. *Leukemia* 1999;13:1497-500.
27. Yuille MR, Condie A, Hudson CD et al. ATM mutations are rare in familial chronic lymphocytic leukemia. *Blood* 2002;100:603-9.
28. Machulla HK, Muller LP, Schaaf A et al. Association of chronic lymphocytic leukemia with specific alleles of the HLA-DR4:DR53:DR8 haplotype in German patients. *Int J Cancer* 2001;92:203-7.
29. Hirose S, Hamano Y, Shirai T. Genetic factors predisposing to B-CLL and to autoimmune disease in spontaneous murine model. *Leukemia* 1997;11(suppl 3):267-70.
30. Bevan S, Catovsky D, Matutes E et al. Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. *Blood* 2000;96:3982-4.
31. Klitz W, Aldrich CL, Fides N et al. Localization of predisposition to Hodgkin's disease in the HLA class II region. *Am J Hum Genet* 1994;54:497-505.
32. Ottensmeier C. The classification of lymphomas and leukemias. *Chemico-Biological Interactions* 2001;135:653-64.
33. Gregersen H, Mellemkjaer L, Ibsen JS et al. Cancer risk in patients with monoclonal gammopathy of undetermined significance. *Am J Hematol* 2000;63:1-6.
34. Kyle RA, Terneau TM, Rajkumar SV et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med* 2002;346:564-9.
35. Chan JK, Ng CS, Isaacson PG. Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. *Am J Pathol* 1990;136:1153-64.
36. Isaacson PG. Lymphomas of mucosa-associated lymphoid tissue (MALT). *Histopathology* 1990;16: 617-22.
37. Jönsson V, Houlston RS, Catovsky et al. CLL family "pedigree14" revisited: 1947-2004. *Leukemia* 2005;19:1025-8.
38. Videbæk Aa. Heredity in human leukemia and its relation to cancer. A genetic and clinical study of 209 probands. London: HK Lewis and Co Publ., 1947:1-278.
39. Bichi R, Shinton SA, Martin ES et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. *Proc Natl Acad Sci USA* 2002;99:6955-60.
40. Bain BB. An overview of translocation-related oncogenesis in chronic myeloid leukaemias. I Bain BB, red. *Chronic myeloproliferative disorders, cytogenetic and molecular genetic abnormalities*. Basel: Karger Verlag, 2003:1-8.

Tilskud til lægemidler

Lægemiddelstyrelsen meddeler, at der pr. 22. maj 2006 ydes generelt tilskud efter sygesikringslovens § 7 til følgende lægemidler:

(G-04-CA-01) Alfuzosin »Winthrop« depottabletter*,
Sanofi-Synthelabo AB
(N-06-AB-03) Fluoxetin »Copyfarm« opløselige tabletter*,
Copyfarm A/S
(R-01-AD-05) Rhinocort Turbohaler næsepudder*,
Abacus Medicine ApS
(R-03-AK-07) Rilast Forte Turbuhaler inhalationspulver*,
Singad Pharma
(N-02-CC-01) Sumatriptan »Sandoz« fillovertrukne
tabletter*, Sandoz GmbH
(G-04-CA-02) Tamsulosinhydrochlorid »Actavis« kapsler*,
Actavis Nordic A/S
(S-01-ED-51) Duotrav øjendråber, Alcon Danmark A/S
(R-03-AC-03) Dracanyl turbuhaler inhalationspulver*,
Abacus Medicine ApS

gruppe uden klausulering over for bestemte sygdomme

Denne bestemmelse trådte i kraft den 22. maj 2006.

*) Omfattet af tilskudsprissystemet.